Transcode Therapeutics begins dosing in fourth cohort of Phase 1 cancer trial

TransCode Therapeutics (RNAZ) announced that the first patient in Cohort 4 of its Phase I clinical trial has received their initial dose. TransCode also reported that two additional patients in Cohort 4 are scheduled to receive TTX-MC138. The therapeutic candidate being evaluated, TTX-MC138, is TransCode’s lead candidate designed to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer. No significant safety or dose limiting toxicities have been reported. The dose administered to the fourth cohort, as originally planned in the clinical protocol, is approximately 50% higher than the dose administered in the third cohort. Of the ten patients treated with TTX-MC138 in the first four cohorts, seven remain on study for continued treatment as there have been no dose limiting toxicities or disease progression in these patients. Pharmacokinetic and pharmacodynamic activity from Cohorts 1, 2 and 3 suggests that TTX-MC138 demonstrates a PK/PD profile consistent with preclinical results and results from TransCode’s Phase 0 clinical trial.